ACADIA to Host Conference Call and Webcast on Wednesday, August 10, 2005 at 4:30 p.m. Eastern Time
SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ —ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2005 on Wednesday, August 10, 2005, after the U.S. financial markets close.
Uli Hacksell, Ph.D., Chief Executive Officer, and Thomas H. Aasen, Vice President and Chief Financial Officer, will host a conference call and webcast on Wednesday, August 10, 2005 at 4:30 p.m. Eastern Time to discuss ACADIA's financial results and provide an update on the company's business.
The conference call may be accessed by dialing 866-700-7477 for participants in the U.S. or Canada and 617-213-8840 for international callers (reference passcode 70881736). A telephone replay of the conference call may be accessed through August 24, 2005 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 28397094). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until August 24, 2005.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, neuropathic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Scandinavia.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
+1 858-558-2871
SOURCE ACADIA Pharmaceuticals Inc.
08/03/2005
Web site: http://www.acadia-pharm.com
(ACAD)
08/03/2005 09:00 EDT http://www.prnewswire.com